Eunice Wang, MD, received her medical training from Keck School of Medicine of the University of Southern California, Los Angeles, CA, in 1996. Dr Wang then completed her residency in internal medicine at the Yale-New Haven Hospital, New Haven, CT, in 1999, followed by her fellowship in hematology/oncology at the Memorial Sloan Kettering Cancer Institute, New York, NY, in 2003.
Dr Wang is currently the Chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, Buffalo, NY, as well as an Associate Professor of Medicine at Jacobs School of Medicine & Biomedical Sciences, University of Buffalo, Buffalo, NY.
Dr Wang is the recipient of several awards such as the Doris Duke “”Bench to Bedside”” Translational Research Award (2002), the Leukemia Lymphoma Society Patient Service Award (2007), and the NCI Cancer Clinical Investigator Team Leadership Award (2013).
Speaking on biology and treatment of acute leukemias and MPNs
Dr Wang’s lab are currently investigating targeted therapeutic approaches on leukemia and lymphoma growth in preclinical trials, as well as the role of marrow microenvironment in treatment-resistance. Dr Wang is also actively involved in studies exploring the correlation of angiogenic factor expression levels with the biological and clinical presentation of leukemia and lymphoma.
Dr Wang is Principal Investigator of various early phase clinical trials such as a Phase I/II trial (NCT04207190) exploring talazoparib and gemtuzumab ozogamicin for CD33-positive relapsed/refractory acute myeloid leukemia (AML) and, more recently, a Phase I trial (NCT04310592) investigating natural killer cell infusions in AML.